Andelyn Biosciences

Andelyn Biosciences is a biopharma, biotechnology, and manufacturing startup that focuses on accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients. Founded in 2020, the company is headquartered in Columbus, OH, USA. With a slogan of "Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients," Andelyn Biosciences is dedicated to Turning Hope into Reality™ through its gene therapy CDMO capabilities. The startup's expertise lies in viral vector process and analytical development, adherent and suspension-based GMP drug substance manufacturing up to 2,000L, as well as GMP plasmid process development and GMP manufacturing. With a 180,000 sq ft clinical and commercial manufacturing facility comprising 16 upstream production suites, Andelyn offers clinical through commercial-scale capabilities for new and tech-transferred programs. Notably, Andelyn has a track record of producing GMP material for over 75 worldwide clinical trials, over 450 cGMP clinical batches, and more than 2,000 research-grade productions. The startup provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, advanced quality systems, full regulatory support, semi-automated to automated fill stations, and supply chain vertical integration. As of 08 February 2022, Andelyn Biosciences secured a $5.00M grant investment from JobsOhio. This investment will likely further bolster the company's position in the gene therapy and vaccine manufacturing space and contribute to its mission of bringing innovative therapies to more patients.